According to research and consulting firm GlobalData, pharmaceutical companies are adopting a broad range of strategies to effectively compete in the tauopathies space. Strategies being adopted include entering into licensing agreements and partnerships for the co-development of products, and pursuing multiple indications and drug candidates.
Brain
GlobalData’s latest report indicates that, given the vast range of unmet needs in neurodegenerative diseases in general, pharmaceutical companies are developing drugs simultaneously in multiple indications, meaning that the same mechanism of action (MOA) can be applied in different indications with little need for additional research, efforts and costs.
“Manufacturers are particularly pursuing Alzheimer’s disease and tauopathies concomitantly,” explained Akiko Fukui, MSc, healthcare analyst for GlobalData. “Since tauopathies share more common disease pathways with Alzheimer’s disease, progress and insight gained in researching the disease can be directly applied to tauopathies drug development and vice versa.
“In addition to targeting multiple indications, another ongoing trend is pursuing multiple compounds in an effort to build a strong portfolio of drugs,” Fukui continued. “This is a good way of balancing pipeline risk and increasing the chances of delivering clinical drug candidates that can modulate the target pathway.”
A very common strategy in the tauopathies market is that companies are entering into licensing partnerships for the co-development of products. This strategy enables companies to join efforts and resources, and share the costs and risks of R&D.
Fukui added, “The discovery stages of potential tauopathy treatments are commonly conducted by small specialist biotechnology companies while the later stages of development are performed by larger and more established companies. For smaller companies, the main advantages of entering in-licensing agreements with larger companies include access to resources for larger trials and teams with capabilities to market and bring the product through the regulatory process.”